---
title: "Varegacestat (AL102) in Desmoid tumors: References"
description: "Reference list for the formulary evidence report on Varegacestat (AL102, BMS-986115) in Desmoid tumors. 177 cited documents."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: References

<a id="references"></a>

## 5 References

1. [Aelvoet et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9636104/)
2. [Agresta et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29384266/)
3. [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)
4. [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)
5. [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)
6. [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)
7. [Bocale et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21831172/)
8. [Bonvalot et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37777684/)
9. [Bouhamama et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37182669/)
10. [Brueckl et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15793634/)
11. [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)
12. [Cazzato et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35237861/)
13. [Chetan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40570819/)
14. [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)
15. [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)
16. [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)
17. [ClinicalTrials.gov NCT01986218](https://clinicaltrials.gov/study/NCT01986218)
18. [ClinicalTrials.gov NCT02476305](https://clinicaltrials.gov/study/NCT02476305)
19. [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)
20. [ClinicalTrials.gov NCT04871282 version 35](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=35)
21. [ClinicalTrials.gov NCT04871282 version 37](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=37)
22. [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)
23. [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)
24. [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)
25. [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264)
26. [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)
27. [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/)
28. [Colombo et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23913621/)
29. [Colombo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35247923/)
30. [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)
31. [Colombo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41903360/)
32. [Constantinidou et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19767198/)
33. [Costa et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39543805/)
34. [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)
35. [Debaudringhien et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9588892/)
36. [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)
37. [Dossa et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42030529/)
38. [Drabbe et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36404250/)
39. [Elnekave et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599870/)
40. [EMA Ogsiveo EPAR (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo)
41. [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127)
42. [EU Clinical Trials Information System 2024-515909-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-515909-26-00)
43. [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)
44. [Express Scripts nirogacestat criteria (2023)](https://express-scripts.com/sites/default/files/policies/Oncology%20-%20Ogsiveo%20PA%20Policy.pdf)
45. [FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005)](https://www.fda.gov/media/71372/download)
46. [FDA orphan drug designation record for varegacestat (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=968423)
47. [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)
48. [FEP Blue nirogacestat policy 5.21.217 (2026)](https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/October/Pharmacy-Policies/Remove-and-Replace-Update/521217-Ogsiveo-nirogacestat.pdf)
49. [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)
50. [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)
51. [Fiore et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24477160/)
52. [Fiore et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26602014/)
53. [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/)
54. [Florida Medicaid oncology prior authorization criteria (2026)](https://ahca.myflorida.com/file/medicaid/Oncology_Criteria_10.01.2026.pdf)
55. [Fouks et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34429254/)
56. [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)
57. [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf)
58. [Garbay et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21444357/)
59. [Garcia-Ortega et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7408653/)
60. [Garg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36350382/)
61. [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)
62. [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)
63. [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)
64. [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)
65. [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)
66. [Gounder et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10474203/)
67. [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)
68. [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)
69. [Gronchi et al. (2021)](https://www.annalsofoncology.org/article/S0923-7534%2821%2902184-0/fulltext)
70. [Hamada et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4006838/)
71. [Hansmann et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14745880/)
72. [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/)
73. [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/)
74. [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)
75. [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)
76. [Immunome expanded access policy](https://immunome.com/patients/)
77. [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)
78. [Immunome Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm)
79. [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)
80. [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)
81. [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)
82. [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)
83. [Immunome press release, first quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/)
84. [Immunome press release, full year 2025 results (2026)](https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/)
85. [Immunome press release, J.P. Morgan 2025 pipeline update (2025)](https://investors.immunome.com/immunome-provides-pipeline-update-in-advance-of-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference/)
86. [Immunome press release, NDA submission (2026)](https://investors.immunome.com/immunome-announces-submission-of-new-drug-application-to-u-s-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)
87. [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)
88. [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)
89. [Immunome press release, second quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-second-quarter-2025-financial-results-and-provides-business-update/)
90. [Immunome press release, second quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-second-quarter-2026-financial-results-and-provides-business-update/)
91. [Immunome press release, third quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update/)
92. [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)
93. [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)
94. [Ingley et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6718598/)
95. [Janssen et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28199014/)
96. [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)
97. [Kasper et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28282612/)
98. [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)
99. [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158)
100. [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)
101. [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)
102. [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)
103. [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)
104. [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/)
105. [Kornreich et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114926/)
106. [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)
107. [Kummar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455706/)
108. [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/)
109. [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)
110. [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/)
111. [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)
112. [Malaviya et al. (2025)](https://springworkstx.com/wp-content/uploads/2025/11/Malaviya_ISPOR-EU_2025_Q-TWiST_POS.pdf)
113. [Mandel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9391920/)
114. [Matsunobu et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32115624/)
115. [Merck KGaA annual report 2025 (2026)](https://reports.emdgroup.com/en/annualreport/2025/management-report/report-on-economic-position/course-of-business-and-economic-position/healthcare.html)
116. [Merck KGaA press release, first quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q1-2026-13-05-2026.html)
117. [Merck KGaA press release, second quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q2-2026-06-08-2026.html)
118. [Merck KGaA press release, third quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q3-2026-12-11-2026.html)
119. [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C118573?include=full)
120. [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)
121. [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)
122. [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat)
123. [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)
124. [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report)
125. [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/)
126. [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)
127. [Nishida et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25899770/)
128. [Nishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7648024/)
129. [Noujaim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38759389/)
130. [Oregon Medicaid prior authorization criteria (2025)](https://www.oregon.gov/oha/HSD/OHP/Tools/Oregon%20Medicaid%20PA%20Criteria%20October%201,%202025.pdf)
131. [Palassini et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28410293/)
132. [Penel et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20622000/)
133. [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)
134. [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)
135. [Penel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883417/)
136. [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)
137. [Quast et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26275868/)
138. [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/)
139. [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)
140. [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/)
141. [Riedel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9546183/)
142. [Rigaux et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25747890/)
143. [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)
144. [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)
145. [Salas et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21844500/)
146. [Saraf et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12191607/)
147. [Sbaraglia et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/)
148. [Schut et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8833407/)
149. [Schut et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9221474/)
150. [Schut et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9994811/)
151. [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)
152. [Shaikh et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39237782/)
153. [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)
154. [Shimizu et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31845730/)
155. [Shimizu et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32700733/)
156. [Singh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41610807/)
157. [Skapek et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17290057/)
158. [Skapek et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4646066/)
159. [Souza et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10766853/)
160. [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)
161. [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)
162. [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)
163. [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)
164. [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/)
165. [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)
166. [Toulmonde et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31331699/)
167. [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/)
168. [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)
169. [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)
170. [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf)
171. [Villalobos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28887726/)
172. [Wang et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22372443/)
173. [Wang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41586907/)
174. [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)
175. [WHO Recommended INN List 92 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/rl92.pdf)
176. [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13223540/)
177. [Zare et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13591399/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
